GlassScriptPhysician profile
Patricia S Poling
NPI 1528010899
$5,535.92
in general payments reported to CMS, 2019-2025
35 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $736 · 2021: $733 · 2022: $740 · 2023: $965 · 2024: $1,050 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $462.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $447.76 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $428.97 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Boston Scientific Corporation | $409.46 | 2023-2024 | Watchman Flx |
| Radius Health, INC. | $383.96 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $339.66 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $321.84 | 2019-2025 | Airsupra |
| Amgen INC. | $302.84 | 2019-2025 | Evenity, Prolia, Repatha |
| Kowa Pharmaceuticals America, INC. | $279.03 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $265.39 | 2019-2025 | Cuvitru, Gattex |
| Novo Nordisk INC | $261.96 | 2022-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.47 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $226.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $220.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $156.97 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $100.11 | 2019-2023 | |
| Axsome Therapeutics, INC. | $81.23 | 2024-2025 | Auvelity |
| Ibsa Pharma INC. | $70.07 | 2021-2025 | Tirosint, Flector, Licart |
| Abbvie INC. | $64.52 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $52.31 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $45.36 | 2022 | |
| Therapeuticsmd, INC. | $44.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $43.16 | 2024-2025 | Voquezna |
| Braemar Manufacturing, LLC | $42.72 | 2019 | |
| Abiomed | $39.25 | 2024 | Impella |
| Almatica Pharma LLC | $37.23 | 2023 | Loreev Xr, Gralise |
| Biohaven Pharmaceutical Holding Company LTD. | $23.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.39 | 2023 | Crysvita |
| Cardiovascular Systems INC. | $22.16 | 2022 | |
| Shire North American Group INC | $17.69 | 2019 | |
| Currax Pharmaceuticals LLC | $17.61 | 2025 | Contrave |
| Kaleo, INC. | $16.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.71 | 2021 | |
| Esperion Therapeutics, INC. | $15.26 | 2021 | |
| Genentech USA, INC. | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.